Sriram Venkataraman insider trades: RVL Pharmaceuticals (RVLP) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sriram reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 8, 2022 | RVLP | ↑ Buy | 8,000,000 | $1.55 | $12.4M | By Avista Capital investment fund | Aug 9, 2022 (1d) |
| Jan 13, 2020 | OSMT | ↑ Buy | 1,250,000 | $5.00 | $6.3M | By Avista Capital investment fund | Jan 15, 2020 (2d) |
| Nov 25, 2019 | OPTN | ↓ Sell | 1,250,000 | $9.16 | $11.5M | Indirect | Nov 26, 2019 (1d) |
| Jun 11, 2018 | OPTN | ↓ Sell | 2,875,000 | $20.91 | $60.1M | Indirect | Jun 13, 2018 (2d) |
| Mar 17, 2017 | LNTH | ↓ Sell | 3,000,000 | $12.20 | $36.6M | Indirect | Mar 21, 2017 (4d) |
| Nov 21, 2016 | LNTH | ↓ Sell | 2,500,000 | $9.00 | $22.5M | Indirect | Nov 23, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Sriram Venkataraman's insider trades
Sriram Venkataraman is a director at RVL Pharmaceuticals (RVLP). Since Nov 21, 2016, Sriram has reported 2 open-market purchases worth $18.6M and 4 sales worth $130.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (4 filings), other transactions (2 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RVLP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.